Business
ANGLE notice of interim results
ANGLE notice of interim results.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n\n\n\n\nFor immediate release\n\n\n15 August 2023\n\n\n\n \nANGLE plc (\"the Company\")\n \nNotice of Interim Results and Webcast\n \nANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative CTC diagnostic solutions for the research and diagnostic oncology market, will be releasing its interim results for the six months ended 30 June 2023 on Thursday 7 September 2023.\n \nA meeting for analysts will be held at 11:00 am BST on Thursday 7 September 2023 at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London EC1A 4HD.\n \nA live webcast of the analyst meeting can be accessed via ANGLE's Investor Centre page, https://angleplc.com/investor-relations/corporate-presentations/, with Q&A participation reserved for analysts only. Please register in advance and log on to the webcast approximately 5 minutes before 11:00 am on the day of the results. A recording of the webcast will be made available on ANGLE's website following the results meeting.\n \nFor further information:\n \n\n\n\nANGLE plc\n\n\n+44 (0) 1483 343434\n\n\n\n\nAndrew Newland, Chief Executive\nIan Griffiths, Finance Director\nAndrew Holder, Head of Investor Relations\n \n\n\n \n \n \n \n\n\n\n\n \nBerenberg (NOMAD and Joint Broker)\nToby Flaux, Ciaran Walsh, Milo Bonser\n\n\n \n+44 (0) 20 3207 7800\n\n\n\n\n \nJefferies (Joint Broker)\nThomas Bective, Shaam Vora\n\n\n \n+44 (0) 20 7029 8000\n \n\n\n\n\n \nFTI Consulting\nSimon Conway, Ciara Martin\nMatthew Ventimiglia (US)\n\n\n \n \n+44 (0) 203 727 1000\n+1 (212) 850 5624\n\n\n\n \n \nFor Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/\n \nNotes for editors\n \nAbout ANGLE plc\n \nANGLE is a world-leading liquid biopsy company with innovative CTC diagnostic solutions for the research and diagnostic oncology market using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumor cell (CTC) harvesting technology known as the Parsortix® system enables complete analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.\n \nANGLE's commercial businesses are focusing on diagnostic products a...